{
    "pubmed_id": 35504289,
    "study_identifier": "PMID35504289_study-01",
    "study_name": "Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer",
    "publication_title": "Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer",
    "study_objective": "There are major knowledge gaps for managing patients with lung cancer in the COVID-19 era which need to be filled. To address these key issues, we prospectively studied the magnitude and kinetics of the humoral response to COVID-19 mRNA vaccination in a well annotated lung cancer population.",
    "study_description": "During the global pandemic with COVID19, early reports indicated that cancer patients in general, and lung cancer patients in particular, who were infected with SARS-CoV-2 had high mortality rates, with a reported 25%\u201340% case fatality rate (CFR) (Rolfo et al., 2022). The underlying clinical, demographic, and tumor-biologic factors contributing to the aggressive course of infection in this vulnerable cancer population have not been fully elucidated and could arise through multiple mechanisms, including the immunosuppressive activity of lung cancer therapeutics, lung cancer itself, or other co-morbidities particularly related to the respiratory system (Kuderer et al., 2020; Zhang et al., 2021; Lievre et al., 2020). In December 2020, phase III randomized clinical trials demonstrated strong clinical efficacy of SARS-CoV-2 mRNA vaccines, which subsequently became available to the public in the United States, but did not specifically evaluate lung cancer patients (Baden et al., 2021; Chavez-Macgregor et al., 2022). Additionally, the recently emergent Omicron variants largely evade vaccination-induced immunity. It has been shown that third mRNA vaccine doses increase Omicron antibody neutralization in the general population; however, the efficacy of this third dose remains unknown in patients with lung cancer (Planas et al., 2022; Wu et al., 2022; Nemet et al., 2022). Thus, there are major knowledge gaps for managing patients with lung cancer in the COVID-19 era which need to be filled",
    "primary_institution_name": "Icahn School of Medicine at Mount Sinai",
    "study_personnel": [
        {
            "personnel_id": "PMID35504289_personnel-01",
            "honorific": "",
            "last_name": "Hirsch",
            "first_name": "Fred",
            "suffixes": "",
            "organization": "Icahn School of Medicine at Mount Sinai",
            "orchid_id": "",
            "email": "fred.hirsch@mssm.edu",
            "seronet_title_in_study": "Seronet Principal Investigator",
            "role_in_study": "Principal Investigator",
            "site_name": "Icahn School of Medicine at Mount Sinai"
        },
        {
            "personnel_id": "PMID35504289_personnel-02",
            "honorific": "",
            "last_name": "Garcia",
            "first_name": "Adolfo",
            "suffixes": "",
            "organization": "Icahn School of Medicine at Mount Sinai",
            "orchid_id": "",
            "email": "adolfo.garcia-sastre@mssm.edu",
            "seronet_title_in_study": "Co-Principal Investigator",
            "role_in_study": "Co-Principal Investigator",
            "site_name": "Icahn School of Medicine at Mount Sinai"
        },
        {
            "personnel_id": "PMID35504289_personnel-03",
            "honorific": "",
            "last_name": "krammer",
            "first_name": "Florian",
            "suffixes": "",
            "organization": "Icahn School of Medicine at Mount Sinai",
            "orchid_id": "",
            "email": "florian.krammer@mssm.edu",
            "seronet_title_in_study": "Investigator",
            "role_in_study": "Investigator",
            "site_name": "Icahn School of Medicine at Mount Sinai"
        }
    ],
    "study_file": [
        {
            "study_file_name": "mmc1.pdf",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "mmc2.pdf",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID35504289_v1.2.2.xlsm",
            "study_file_description": "Completed curation of the study into SeroNet Registry Template which includes SeroNet Study Descriptors.",
            "study_file_type": "Study Summary Description"
        }
    ],
    "study_link": [],
    "research_focus": "Immune Response",
    "study_type": "Clinical Research",
    "keyword": [
        "Not provided"
    ],
    "clinical_study_design": "Longitudinal Study",
    "in_silico_model_type": "",
    "protocol": {
        "protocol_id": "PMID35504289_protocol-01",
        "protocol_file_name": "PMID35504289_protocol-01.txt",
        "protocol_name": "PMID35504289_protocol-01",
        "protocol_description": "Study Protocol",
        "protocol_type": "Study Protocol"
    },
    "reported_health_condition": [
        "Covid-19",
        "Lung Cancer"
    ],
    "sars_cov_2_vaccine_type": [
        "Pfizer-BioNTech",
        "Moderna",
        "Johnson & Johnson"
    ],
    "clinical_outcome_measure": "Humoral response to COVID-19 mRNA vaccination",
    "enrollment_start_date": "",
    "enrollment_end_date": "",
    "number_of_study_subjects": 294,
    "age_unit": "Years",
    "minimum_age": "",
    "maximum_age": "",
    "study_human_cohort": [
        {
            "arm_id": "PMID35504289_human_subject-01",
            "arm_name": "Lung cancer patients enrolled in the study",
            "study_population_description": "176 lung cancer patients enrolled in the study",
            "arm_type": "Vaccination",
            "ethnicity": [
                "Hispanic or Latino",
                "Not Hispanic or Latino"
            ],
            "race": [
                "Asian",
                "Black or African American",
                "Native Hawaiian or Other Pacific Islander",
                "Other",
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Female",
                "Male",
                "Unknown"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": [],
            "assessment_name": "assessment_recorded_pv",
            "study_location": [
                "US: New York"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated",
                "Not vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987",
                "Moderna COVID-19 vaccine ; VO:0005157",
                "Johnson & Johnson COVID-19 vaccine; VO:0005159"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35504289_human_subject-02",
            "arm_name": "Vaccinated Lung cancer patients",
            "study_population_description": "114 lung cancer patients who received two doses of Covid-19 vaccination",
            "arm_type": "Vaccination",
            "ethnicity": [
                "Hispanic or Latino",
                "Not Hispanic or Latino"
            ],
            "race": [
                "Asian",
                "Black or African American",
                "Native Hawaiian or Other Pacific Islander",
                "Other",
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Female",
                "Male",
                "Unknown"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": [],
            "assessment_name": "assessment_recorded_pv",
            "study_location": [
                "US: New York"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987",
                "Moderna COVID-19 vaccine ; VO:0005157"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35504289_human_subject-03",
            "arm_name": "Control subjects",
            "study_population_description": "A total of 114 control subjects enrolled in the study",
            "arm_type": "Vaccination",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Female",
                "Male",
                "Unknown"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": [],
            "assessment_name": "assessment_recorded_pv",
            "study_location": [
                "US: New York"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987",
                "Moderna COVID-19 vaccine ; VO:0005157"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35504289_human_subject-04",
            "arm_name": "Control subjects from ELCAP study",
            "study_population_description": "Out of 114 total control subjects, 51 are from the Early lung and Cancer action program (ELCAP) lung cancer screening",
            "arm_type": "Vaccination",
            "ethnicity": [
                "Hispanic or Latino",
                "Not Hispanic or Latino"
            ],
            "race": [
                "Asian",
                "Black or African American",
                "Native Hawaiian or Other Pacific Islander",
                "Other",
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Female",
                "Male",
                "Unknown"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": [],
            "assessment_name": "assessment_recorded_pv",
            "study_location": [
                "US: New York"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987",
                "Moderna COVID-19 vaccine ; VO:0005157",
                "Johnson & Johnson COVID-19 vaccine; VO:0005159"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35504289_human_subject-05",
            "arm_name": "Control subjects from PARIS study group",
            "study_population_description": "Out of 114 total control subjects, 67 are from the protection associated with rapid immunity to SARS-CoV-2 (PARIS) study",
            "arm_type": "Vaccination",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Female",
                "Male",
                "Unknown"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": [],
            "assessment_name": "assessment_recorded_pv",
            "study_location": [
                "US: New York"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaaccinated I Infected  I Uninfected"
            ],
            "sars_cov_2_vaccine_type": [
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987",
                "Moderna COVID-19 vaccine ; VO:0005157"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        }
    ],
    "study_model_cohort": [],
    "planned_visit": [
        {
            "visit_id": "PMID35504289_visit-01",
            "visit_name": "Blood collected at baseline from individuals who received Pfizer, moderna and J & J vaccination",
            "visit_order_number": 1,
            "visit_min_start_day": 0,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-02",
            "visit_name": "Blood collected after 14 days of two doses of mRNA vaccination",
            "visit_order_number": 2,
            "visit_min_start_day": 14,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-03",
            "visit_name": "Antibody titers compared between lung cancer patients and controls after 100 days of two doses of pfizer vaccination.",
            "visit_order_number": 3,
            "visit_min_start_day": 121,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-04",
            "visit_name": "Antibody titers compared between lung cancer patients and controls after 250 days of two doses of pfizer vaccination.",
            "visit_order_number": 4,
            "visit_min_start_day": 271,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-05",
            "visit_name": "Antibody titers compared between lung cancer patients and controls after 300 days of two doses of pfizer vaccination.",
            "visit_order_number": 5,
            "visit_min_start_day": 321,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-06",
            "visit_name": "Antibody titers compared between lung cancer patients and controls after 100 days of two doses of moderna vaccination.",
            "visit_order_number": 6,
            "visit_min_start_day": 128,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-07",
            "visit_name": "Antibody titers compared between lung cancer patients and controls after 250 days of two doses of moderna vaccination.",
            "visit_order_number": 7,
            "visit_min_start_day": 278,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-08",
            "visit_name": "Antibody titers compared between lung cancer patients and controls after 300 days of two doses of moderna vaccination.",
            "visit_order_number": 8,
            "visit_min_start_day": 328,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-09",
            "visit_name": "Antibody titers compared between lung cancer patients and controls after 100 days of two doses J & J vaccination.",
            "visit_order_number": 9,
            "visit_min_start_day": 100,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-10",
            "visit_name": "Antibody titers compared between lung cancer patients and controls after 250 days of two doses J & J vaccination.",
            "visit_order_number": 10,
            "visit_min_start_day": 250,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-11",
            "visit_name": "Antibody titers compared between lung cancer patients and controls after 300 days of two doses J & J vaccination.",
            "visit_order_number": 11,
            "visit_min_start_day": 300,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-12",
            "visit_name": "Blood collected at 3 months from individuals who received Pfizer, moderna and J & J vaccination",
            "visit_order_number": 12,
            "visit_min_start_day": 90,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-13",
            "visit_name": "Blood collected at 6 months from individuals who received Pfizer, moderna and J & J vaccination",
            "visit_order_number": 13,
            "visit_min_start_day": 180,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-14",
            "visit_name": "Blood collected at 12 months from individuals who received Pfizer, moderna and J & J vaccination",
            "visit_order_number": 14,
            "visit_min_start_day": 365,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-15",
            "visit_name": "Blood collected at 24 months from individuals who received Pfizer, moderna and J & J vaccination",
            "visit_order_number": 15,
            "visit_min_start_day": 730,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35504289_visit-16",
            "visit_name": "After third dose of pfizer mRNA vaccineSera, plasma from lung cancer patients and healthy controls taken 4-10 weeks .",
            "visit_order_number": 16,
            "visit_min_start_day": 178,
            "visit_max_start_day": 220,
            "visit_start_rule": ""
        }
    ],
    "experiment": [
        {
            "arm_id": [
                "PMID35504289_human_subject-02",
                "PMID35504289_human_subject-04",
                "PMID35504289_human_subject-05"
            ],
            "associated_first_planned_visit_id": [
                "PMID35504289_visit-03",
                "PMID35504289_visit-04",
                "PMID35504289_visit-05",
                "PMID35504289_visit-06",
                "PMID35504289_visit-07",
                "PMID35504289_visit-08"
            ],
            "assay_type": [
                "ELISA"
            ],
            "experiment_name": [
                "SARS-CoV-2 binding antibody assessment"
            ],
            "experiment_results_file_name": [
                "na"
            ],
            "biospecimen_type": [
                "Plasma"
            ],
            "sars_cov_2_antigen": [
                "Full Length Spike Trimer"
            ],
            "assay_use": [],
            "manufacture": [],
            "catalog_number": [],
            "virus_target": [
                "Full-length SARS-CoV-2 spike ectodomain"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": [],
            "assay_reporting_format": [
                "Quantitative"
            ]
        },
        {
            "arm_id": [
                "PMID35504289_human_subject-02",
                "PMID35504289_human_subject-05",
                "PMID35504289_organism_subject-06"
            ],
            "associated_first_planned_visit_id": [
                "PMID35504289_visit-16"
            ],
            "assay_type": [
                "Pseudovirus Neutralization Assay"
            ],
            "experiment_name": [
                "SARS-CoV-2 neutralization assay"
            ],
            "experiment_results_file_name": [
                "na"
            ],
            "biospecimen_type": [
                "Serum I Plasma"
            ],
            "sars_cov_2_antigen": [],
            "assay_use": [],
            "manufacture": [],
            "catalog_number": [],
            "virus_target": [],
            "antibody_isotype": [],
            "reporting_units": [],
            "assay_reporting_format": [
                "Quantitative"
            ]
        }
    ],
    "geriatric_subjects": "Y",
    "pediatric_subjects": "N",
    "inclusion_exclusion": [
        {
            "inclusion_exculusion_id": "PMID35504289_inexcl-01",
            "inclusion_criterion": "Geriatric subjects",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35504289_inexcl-02",
            "inclusion_criterion": "Pediatric subjects",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35504289_inexcl-03",
            "inclusion_criterion": "Lung cancer patients",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35504289_inexcl-04",
            "inclusion_criterion": "Vaccine receipents",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35504289_inexcl-05",
            "inclusion_criterion": "SARS-CoV-2 Antibodies Measured",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35504289_inexcl-06",
            "inclusion_criterion": "Participants enrolled after third dose of vaccination",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35504289_inexcl-07",
            "inclusion_criterion": "Participants who failed to receive 2 doses of vaccination",
            "inclusion_criterion_category": "exclusion"
        }
    ]
}
